Trial Profile
Phase II Open-label Study to Evaluate the Efficacy and Safety of Radium in Combination With External Beam Radiotherapy (EBRT) vs. EBRT Alone in the Treatment of Castration Resistant Prostate Carcinoma With Limited Bone Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Carcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms alpha-RT
- 01 Aug 2017 Status changed from recruiting to completed.
- 02 Jul 2015 New trial record